Lobbying disclosures · Lobbying report
ALNY: third_quarter 2026 lobbying report
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; U.S. Competitiveness FDA modernization
Follow ALNY- Became public
- Oct 20, 2026, 4:07 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 6:58 PM EST
Why this is connected
Exact legal-name match: ALNYLAM PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1178670/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/edcec90d-d6e0-41b2-b05a-4a50094264b2/","filing_uuid":"edcec90d-d6e0-41b2-b05a-4a50094264b2","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/edcec90d-d6e0-41b2-b05a-4a50094264b2/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Sarah Egge","dt_posted":"2026-10-20T16:07:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"300 New Jersey Avenue, NW","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":401104582,"url":"https://lda.gov/api/v1/registrants/401104582/","house_registrant_id":null,"name":"SPLITOAK STRATEGIES LLC","description":"Health care consulting","address_1":"300 New Jersey Avenue, NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARAH EGGE","contact_telephone":"+1 703-203-7992","dt_updated":"2026-07-30T12:56:37.934245-04:00"},"client":{"id":202097,"url":"https://lda.gov/api/v1/clients/202097/","client_id":90,"name":"ALNYLAM PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-11-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; U.S. Competitiveness","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67714,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"KUEHL","last_name":"EGGE","suffix":null,"suffix_display":null},"covered_position":"1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction","new":false},{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":"1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FDA modernization","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67714,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"KUEHL","last_name":"EGGE","suffix":null,"suffix_display":null},"covered_position":"Sarah: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction","new":false},{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":"Amy: 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in ALNY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 9, 2026$1K–$15K
Sen. Cory A. Booker (D-NJ)
Sold (full) Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Aug 11, 2026 · disclosed Sep 9, 2026 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Feb 15, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Jan 29, 2024 · disclosed Feb 15, 2024 · Joint
- Feb 15, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Jan 11, 2024 · disclosed Feb 15, 2024 · Joint
- Jan 7, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Dec 11, 2023 · disclosed Jan 7, 2024 · Joint
- Apr 17, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Bought Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 24, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.